Syndax Pharmaceuticals, Inc. Stock price

Equities

SNDX

US87164F1057

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
23.8 USD +3.16% Intraday chart for Syndax Pharmaceuticals, Inc. +4.02% +10.13%
Sales 2024 * 31.42M Sales 2025 * 121M Capitalization 2.02B
Net income 2024 * -312M Net income 2025 * -251M EV / Sales 2024 * 55.1 x
Net cash position 2024 * 291M Net cash position 2025 * 223M EV / Sales 2025 * 14.8 x
P/E ratio 2024 *
-6.37 x
P/E ratio 2025 *
-8.61 x
Employees 184
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.24%
More Fundamentals * Assessed data
Dynamic Chart
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia CI
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment MT
Syndax Says Revumenib NDA Granted FDA Priority Review DJ
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia CI
JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Rise Monday Afternoon MT
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer MT
Syndax Pharmaceuticals, Inc. Announces Executive Changes CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Transcript : Syndax Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 11:00 AM
Certain Restricted Stock Units of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
Certain Stock Options of Syndax Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-FEB-2024. CI
More news
1 day+3.16%
1 week+4.02%
Current month+1.54%
1 month-0.34%
3 months+10.24%
6 months+52.27%
Current year+10.13%
More quotes
1 week
21.42
Extreme 21.42
24.19
1 month
21.42
Extreme 21.42
25.16
Current year
19.58
Extreme 19.58
25.34
1 year
11.22
Extreme 11.215
25.34
3 years
11.22
Extreme 11.215
29.86
5 years
4.82
Extreme 4.82
29.86
10 years
3.39
Extreme 3.39
29.86
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 15-05-04
Founder 55 05-10-10
President - 23-04-09
Members of the board TitleAgeSince
Director/Board Member 52 17-03-28
Chairman 66 08-11-30
Director/Board Member 63 17-01-03
More insiders
Date Price Change Volume
24-03-28 23.8 +3.16% 1,058,374
24-03-27 23.07 +7.60% 1,190,999
24-03-26 21.44 -4.46% 1,248,893
24-03-25 22.44 -0.62% 825,478
24-03-22 22.58 -1.31% 1,076,996

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
23.8 USD
Average target price
35.17 USD
Spread / Average Target
+47.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Syndax Pharmaceuticals, Inc. - Nasdaq